-
Solanezumab (proposed INN, LY2062430) is a
monoclonal antibody being investigated by Eli
Lilly as a
neuroprotector for
patients with Alzheimer's disease...
- III
clinical trial.
Solanezumab, an anti-Aβ mAb,
targets the N-terminus of Aβ. In
Phase I and
Phase II of
clinical trials,
Solanezumab treatment resulted...
- the USP
Dictionary or in the WHO INN stembook. If the name of the drug
solanezumab were to be
broken down, it
would be
divided into two
parts like this:...
- fluid. In a double-blind
trial of the
humanised monoclonal antibody solanezumab (n = 2042),
sixteen patients (11
taking the drug, 5
taking a placebo)...
- amyloid-modifying therapies.
Human monoclonal antibodies such as aducanumab,
solanezumab, and
bapineuzumab have been ****ociated with
these neuroimaging changes...
-
treatment of Alzheimer's disease.
Crenezumab is
highly homologous to
solanezumab,
another monoclonal antibody targeting amyloid-β peptides. In June 2022...
-
rheumatoid arthritis Sofituzumab vedotin mab
humanized CA-125
ovarian cancer Solanezumab mab
humanized β-amyloid Alzheimer's
disease Solitomab BiTE
mouse EpCAM...
-
included aducanumab, bapineuzumab, crenezumab, gantenerumab, lecanemab, and
solanezumab.
Imaging compounds,
notably Pittsburgh compound B, (6-OH-BTA-1, a thioflavin)...
- (INN) Sofra-Tulle
sograzepide (USAN)
Sohonos solabegron (INN)
Solage solanezumab (USAN, INN)
Solaquin Solaraze Solarcaine solasulfone (INN)
Solatene Solfoton...
- just
three months after Eli
Lilly & Co.
announced its own
setback with
solanezumab. In
September 2014
AstraZeneca and Eli
Lilly and
Company announced an...
